famitinib   Click here for help

GtoPdb Ligand ID: 7886

Synonyms: compound 9 [PMID: 21028894] | SHR 1020 | SHR-1020 | SHR1020
Compound class: Synthetic organic
Comment: Famitinib is a multi-targeted receptor tyrosine kinase inhibitor [1]. The compound is a structural analogue of sunitinib.
The INN famitinib appeared in Proposed List 125 which was published by the WHO at the end of July 2021.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 68.44
Molecular weight 410.21
XLogP 2.59
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCN(CCN1CCc2c(C1=O)c(C)c([nH]2)C=C1C(=O)Nc2c1cc(F)cc2)CC
Isomeric SMILES CCN(CCN1CCc2c(C1=O)c(C)c([nH]2)/C=C/1\C(=O)Nc2c1cc(F)cc2)CC
InChI InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-
No information available.
Summary of Clinical Use Click here for help
Famitinib has progressed to Phase 3 clinical evaluation in advanced colorectal adenocarcinoma and non-squamous NSCLC. A number of Phase 2 trials in other advanced solid tumour types have been completed. Click here to link to ClinicalTrials.gov's full list of famitinib trials.